Board expansion Perrigo has recently appointed independent directors Salman Amin and Omer Gajial, signaling governance strengthening and potential strategic pivots. This presents an opening to engage at the board and executive levels on initiatives aligned with governance-driven efficiency, risk management, and strategic partnerships.

Leadership shift Interim CEO appointment after the departure of the prior CEO indicates transitional leadership and potential strategic realignment. Prospect for conversations around continuity plans, product portfolio optimization, and accelerated initiatives in consumer self-care lines.

Cybersecurity emphasis A cybersecurity incident involving employee email accounts highlights security posture needs. Opportunity to offer cybersecurity hardening services, phishing resistance programs, and secure communications solutions to protect sensitive healthcare and regulatory data.

Portfolio optimization Sale of the branded Dermacosmetics business to Karo Group for up to €332.6 million suggests ongoing portfolio refinement. This creates openings for partnerships in remaining OTC and Rx lines, as well as opportunities to provide manufacturing efficiency, quality, and regulatory support for core products.

Financial scale gap With revenue in the $50M–$100M range and a lean employee base, Perrigo may be pursuing scalable, cost-efficient supplier partnerships. Target opportunities include contract manufacturing, API sourcing, formulation development, and IT/ERP modernization to support growth without extensive overhead.